ELEVAI LABS will launch its core technology platform, PREx (Precision Regenerative Exosome Technology) at The American Society for Laser Medicine and Surgery (ASLMS) Annual Meeting on April 13, 2023.
PREx, ELEVAI's technology platform, utilizes the power of exosome, nanoparticle compartments that contain growth factors, to optimize the appearance of skin and improve the patient experience. All of the brand's science-backed formulations feature ELEVAI Exosomes as the primary ingredient that mimics the biological factors of nature involved in repair and recovery, which supports the skin's natural healing process.
Related: Ingredient Spotlight: MSC Exosome Technology
"Behind everything we do is the desire to provide innovative, safe, high-quality, and efficacious formulations." said ELEVAI LABS' co-founder, Dr. Jordan Plews. "We are excited to unveil PREx at the ASLMS Meeting and share our transformative approach to topical exosome skin care. New data suggests ELEVAI's proprietary PREx Technology helps aesthetic providers deliver improved results for patients, contributing towards reduced recovery time and improved outcomes."
During ASLMS, ELEVAI will lead the conversation around topical exosomes and their transformative approach to pre- and post-procedural skin care. Dr. Jordan Plews and Dr. Natalie Curcio will unveil PREs, while also presenting new data quantifying the appearance of the reduction of redness and pigmentation in subjects' skin at week eight and week twelve of daily topical application of ELEVAI products, obtained through the Canfield Reveal Imaging System.
